The CDRT15L2 antibody is a monoclonal antibody primarily used in research to detect the CDRT15L2 protein, a poorly characterized antigen with potential roles in cellular signaling or disease pathways. Although limited public data exists, CDRT15L2 is speculated to belong to a family of proteins involved in membrane-associated processes, possibly linked to neurological disorders or cancer progression. This antibody is commonly employed in immunohistochemistry (IHC), Western blotting, and immunofluorescence to localize and quantify CDRT15L2 expression in tissue samples or cell lines. Its development likely stems from interest in identifying novel biomarkers or therapeutic targets, particularly in oncology, where aberrant protein expression patterns may correlate with tumor aggressiveness or drug resistance. The antibody’s immunogen, host species (often rabbit or mouse), and specific epitope remain undisclosed in public databases, highlighting the need for further validation studies. Researchers utilize CDRT15L2 antibody to explore its involvement in cellular functions such as adhesion, proliferation, or apoptosis, though conclusive mechanistic insights are still pending. Commercial availability through niche biotech suppliers suggests specialized applications, urging users to verify cross-reactivity and optimize protocols for experimental reproducibility.